Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy


Autoria(s): Aikawa, Nádia Emi; Sallum, A. M. E.; Pereira, R. M. R.; Suzuki, L.; Viana, V. S. T.; Bonfa, E.; Silva, C. A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

07/11/2013

07/11/2013

2012

Resumo

Objective To perform systematic assessment of ovarian reserve markers using a combination of tests in juvenile systemic lupus erythematosus (JSLE) patients without amenorrhoea. Methods Twenty-seven consecutive JSLE female patients and 13 healthy controls without amenorrhoea were evaluated for 6 months. Ovarian reserve was assessed during early follicular phase by serum levels of follicle stimulating hormone (FSH), luteinising hormone (LH), estradiol, inhibin A, inhibin B and anti-Mullerian hormone (AMH). Ovarian size was measured by abdominal ultrasonography. Demographic data, disease activity, damage and treatment were also analysed. Results The median of current age was similar in ISLE patients and controls (16.5 vs. 15years, p=0.31) with a significantly higher age at menarche (13 vs. 12years, p=0.03). A trend of lower median total antral follicle count was observed in JSLE compared to controls (9 vs. 14.5, p=0.062) with similar median of other ovarian reserve parameters (p>0.05). Further evaluation of patients treated with cyclophosphamide and those without this treatment revealed a higher median FSH levels (6.4 vs. 4.6 IU/L, p=0.023). Inhibin B, AMH levels and ovarian volume were also lower but did not reach statistical significance (10.8 vs. 27.6 pg/mL, p=0.175; 0.6 vs. 1.5 ng/mL, p=0.276; 3.4 vs. 5 cm(3), p=0.133; respectively). LH (2.7 vs. 2.9 IU/L, p=0.43), estradiol (50 vs. 38 pg/mL, p=0.337) and inhibin A (1.1 vs. 0 pg/mL, p=0.489) levels were comparable in both groups. Conclusions Our study suggests that ovarian reserve after cyclophosphamide treatment may be hampered in spite of the presence of menstrual cycles emphasising the relevance of gonadal protection during the use of this alkylating agent.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [472953/2008-7, 302724/2011-7, 301411/2009-3, 300559/2009-7]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Federico Foundation

Federico Foundation

Identificador

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, PISA, v. 30, n. 3, pp. 445-449, MAY-JUN, 2012

0392-856X

http://www.producao.usp.br/handle/BDPI/43311

Idioma(s)

eng

Publicador

CLINICAL & EXPER RHEUMATOLOGY

PISA

Relação

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

Direitos

restrictedAccess

Copyright CLINICAL & EXPER RHEUMATOLOGY

Palavras-Chave #JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS #OVARIAN RESERVE #INHIBIN A #INHIBIN B #ANTI-MULLERIAN HORMONE #ANTI-MULLERIAN HORMONE #DISEASE-ACTIVITY #GONADAL-FUNCTION #CHILDHOOD #WOMEN #RHEUMATOLOGY
Tipo

article

original article

publishedVersion